Sanctuary Advisors LLC boosted its stake in shares of Paysign, Inc. (NASDAQ:PAYS – Free Report) by 4.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 121,089 shares of the company’s stock after acquiring an additional 5,000 shares during the quarter. Sanctuary Advisors LLC owned 0.23% of Paysign worth $419,000 at the end of the most recent reporting period.
A number of other large investors also recently bought and sold shares of PAYS. Joule Financial LLC purchased a new position in shares of Paysign during the 3rd quarter valued at approximately $1,478,000. Renaissance Technologies LLC increased its holdings in Paysign by 25.0% in the second quarter. Renaissance Technologies LLC now owns 1,504,380 shares of the company’s stock valued at $6,484,000 after buying an additional 301,000 shares in the last quarter. Royce & Associates LP acquired a new position in shares of Paysign in the third quarter worth about $814,000. Dimensional Fund Advisors LP boosted its stake in shares of Paysign by 51.5% during the 2nd quarter. Dimensional Fund Advisors LP now owns 116,779 shares of the company’s stock worth $502,000 after acquiring an additional 39,710 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Paysign by 327.4% during the 3rd quarter. Barclays PLC now owns 47,090 shares of the company’s stock valued at $173,000 after acquiring an additional 36,071 shares during the period. 25.89% of the stock is owned by institutional investors and hedge funds.
Insiders Place Their Bets
In other Paysign news, CEO Mark Newcomer sold 22,000 shares of the business’s stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $3.75, for a total value of $82,500.00. Following the transaction, the chief executive officer now directly owns 9,414,886 shares in the company, valued at $35,305,822.50. The trade was a 0.23 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Matthew Louis Lanford sold 25,360 shares of the firm’s stock in a transaction that occurred on Friday, November 8th. The stock was sold at an average price of $3.96, for a total transaction of $100,425.60. Following the sale, the insider now owns 109,731 shares of the company’s stock, valued at $434,534.76. This represents a 18.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 189,360 shares of company stock valued at $661,746 in the last three months. 23.30% of the stock is currently owned by insiders.
Analyst Ratings Changes
Read Our Latest Analysis on Paysign
Paysign Trading Up 9.2 %
Shares of NASDAQ PAYS opened at $3.32 on Friday. The stock has a market cap of $177.78 million, a PE ratio of 22.13 and a beta of 0.93. Paysign, Inc. has a 12-month low of $2.40 and a 12-month high of $5.59. The company has a 50-day moving average of $3.46 and a 200 day moving average of $4.04.
Paysign (NASDAQ:PAYS – Get Free Report) last posted its quarterly earnings results on Tuesday, November 5th. The company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.02. Paysign had a return on equity of 30.64% and a net margin of 14.28%. The business had revenue of $15.26 million during the quarter, compared to analyst estimates of $14.96 million. During the same period in the prior year, the business earned $0.02 earnings per share. On average, sell-side analysts forecast that Paysign, Inc. will post 0.21 EPS for the current fiscal year.
Paysign Profile
Paysign, Inc provides prepaid card programs, comprehensive patient affordability offerings, digital banking services, and integrated payment processing services for businesses, consumers, and government institutions. Its product offerings include solutions for corporate rewards, prepaid gift cards, general purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts accessible with a debit card.
Featured Articles
- Five stocks we like better than Paysign
- What is a SEC Filing?
- Top 3 Investment Themes to Watch for in 2025
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Mega Buybacks in 2025: Why These 3 Leading Stocks Are Buys
- Insider Buying Explained: What Investors Need to Know
- AMD vs. NVIDIA: The Better Semiconductor Bet for 2025
Receive News & Ratings for Paysign Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paysign and related companies with MarketBeat.com's FREE daily email newsletter.